Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information

Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23.

Authors

Paola Minetto¹, Fabio Guolo¹, Marino Clavio¹, Annalisa Kunkl², Nicoletta Colombo¹, Enrico Carminati¹, Giuseppina Fugazza¹, Simona Matarese¹, Daniela Guardo¹, Filippo Ballerini¹, Carmen Di Grazia³, Anna M Raiola³, Antonia Cagnetta¹, Michele Cea¹, Maurizio Miglino¹, Roberto M Lemoli¹, Marco Gobbi¹

Affiliations

¹ Haematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy.
² Clinical Flow Cytometry Unit, Anatomic Pathology, Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy.
³ Division of Haematology and Bone Marrow Transplantation, Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy.

PMID: 29359798
DOI: 10.1111/bjh.15106

No abstract available

Keywords: acute myeloid leukaemia; flow cytometry; fludarabine; fludarabine, cytarabine, idarubicin; minimal residual disease.

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cytarabine / administration & dosage
Disease-Free Survival
Female
Humans
Idarubicin / administration & dosage
Leukemia, Myeloid, Acute / blood*
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / mortality*
Male
Middle Aged
Neoplasm, Residual
Survival Rate
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Cytarabine
Vidarabine
fludarabine
Idarubicin